scholarly journals CHRONIC VIRAL HEPATITIS AND INFLAMMATORY BOWEL DISEASE

2021 ◽  
Vol 5 (2) ◽  
pp. 111-117
Author(s):  
G. V. Volynets ◽  

The article presents the results of a literature review devoted to the study of the problems of the concurrent course of inflammatory bowel diseases (IBD), which include ulcerative colitis (UC) and Crohn's disease (CD), as well as chronic viral hepatitis (CVH) - chronic hepatitis B (CHB) and chronic hepatitis C (CHC). The prevalence of CHB and CHC in IBD in different countries ranges from 1% to 9%. The clinical course of these concurrent diseases, the possibility of hepatitis B virus (HBV) and hepatitis C virus (HCV) reactivation during immunosuppressive therapy are described. Recommendations on the peculiarities of examination and management of patients with concurrent pathology of IBD and CVH are presented. The combined pathology of IBD and CVH is a significant public health problem worldwide that requires further largescale study. The use of immunosuppressive therapy for IBD can be accompanied by the activation of HBV and HCV infection, therefore, the management of such patients should occur on an individual basis.

2021 ◽  
Vol 11 (2) ◽  
pp. 29-34
Author(s):  
G.V. Volynets ◽  
◽  
A.I. Khavkin ◽  

The article presents the results of a literature review devoted to the study of the problems of the combined course of inflammatory bowel diseases (IBD), which include ulcerative colitis (UC) and Crohn's disease (CD), and chronic viral hepatitis (CVH) – chronic hepatitis B (CHB) and chronic hepatitis C (CHC). The frequency of occurrence of CHB and CHC in IBD in different countries is presented, which ranges from 1 to 9%. The clinical course of these combined diseases, the possibility of reactivation of hepatitis B virus (HBV) and hepatitis C virus (HCV) during immunosuppressive therapy are described. Recommendations on the specifics of examination and management of patients with combined pathology of IBD and CVH are presented. Conclusion. The combined pathology of IBD and CVH is a significant public health problem around the world that requires further large-scale study. The use of immunosuppressive therapy for IBD can be accompanied by the activation of HBV and HCV infection, therefore, the management of such patients should be individualized. Key words: inflammatory bowel disease, chronic hepatitis B, chronic hepatitis C, immunosuppressive therapy


2004 ◽  
Vol 18 (12) ◽  
pp. 715-728 ◽  
Author(s):  
Morris Sherman ◽  
Vincent Bain ◽  
Jean-Pierre Villeneuve ◽  
Robert P Myers ◽  
Curtis Cooper ◽  
...  

Several government and nongovernment organizations held a consensus conference on the management of acute and chronic viral hepatitis to update previous management recommendations. The conference became necessary because of the introduction of new forms of therapy for both hepatitis B and hepatitis C. The conference issued recommendations on the investigation and management of chronic hepatitis B, including the use of lamivudine, adefovir and interferon. The treatment of hepatitis B in several special situations was also discussed. There were also recommendations on the investigation and treatment of chronic hepatitis C and hepatitis C-HIV coinfection. In addition, the document makes some recommendations about the provision of services by provincial governments to facilitate the delivery of care to patients with hepatitis virus infection. The present document is meant to be used by practitioners and other health care providers, including public health staff and others not directly involved in patient care.


mBio ◽  
2015 ◽  
Vol 6 (6) ◽  
Author(s):  
Sara R. Selitsky ◽  
Timothy A. Dinh ◽  
Cynthia L. Toth ◽  
C. Lisa Kurtz ◽  
Masao Honda ◽  
...  

ABSTRACT Chronic hepatitis B (CHB), chronic hepatitis C (CHC), and associated hepatocellular carcinoma (HCC) are characterized by cholesterol imbalance and dyslipidemia; however, the key regulatory drivers of these phenotypes are incompletely understood. Using gene expression microarrays and high-throughput sequencing of small RNAs, we performed integrative analysis of microRNA (miRNA) and gene expression in nonmalignant and matched cancer tissue samples from human subjects with CHB or CHC and HCC. We also carried out follow-up functional studies of specific miRNAs in a cell-based system. These studies led to four major findings. First, pathways affecting cholesterol homeostasis were among the most significantly overrepresented among genes dysregulated in chronic viral hepatitis and especially in tumor tissue. Second, for each disease state, specific miRNA signatures that included miRNAs not previously associated with chronic viral hepatitis, such as miR-1307 in CHC, were identified. Notably, a few miRNAs, including miR-27 and miR-224, were components of the miRNA signatures of all four disease states: CHB, CHC, CHB-associated HCC, and CHC-associated HCC. Third, using a statistical simulation method (miRHub) applied to the gene expression data, we identified candidate master miRNA regulators of pathways controlling cholesterol homeostasis in chronic viral hepatitis and HCC, including miR-21, miR-27, and miR-33. Last, we validated in human hepatoma cells that both miR-21 and miR-27 significantly repress cholesterol synthesis and that miR-27 does so in part through regulation of the gene that codes for the rate-limiting enzyme 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase (HMGCR). IMPORTANCE Hepatitis B virus (HBV) and hepatitis C virus (HCV) are phylogenetically unrelated hepatotropic viruses that persistently infect hundreds of millions of people world-wide, often leading to chronic liver disease and hepatocellular carcinoma (HCC). Chronic hepatitis B (CHB), chronic hepatitis C (CHC), and associated HCC often lead to cholesterol imbalance and dyslipidemia. However, the regulatory mechanisms underlying the dysregulation of lipid pathways in these disease states are incompletely understood. MicroRNAs (miRNAs) have emerged as critical modulators of lipid homeostasis. Here we use a blend of genomic, molecular, and biochemical strategies to identify key miRNAs that drive the lipid phenotypes of chronic viral hepatitis and HCC. These findings provide a panoramic view of the miRNA landscape in chronic viral hepatitis, which could contribute to the development of novel and more-effective miRNA-based therapeutic strategies.


2021 ◽  
Vol 13 (1) ◽  
pp. 88-96
Author(s):  
S. S. Sleptsova ◽  
S. S. Sleptsov ◽  
V. K. Semenova

Hepatitis C is a major public health problem and measures against it require the development of a national strategy and concept of a prognostic model. This is relevant for Yakutia, as a tremendous region with extremely specific and severe climatic and social conditions that cause a high incidence of hepatitis C.Objective: to evaluate the effectiveness of various scenarios for the development of the epidemiological situation of hepatitis C in RS (Y) depending on the strategy for providing medical care to people with chronic hepatitis C.Material and Methods. The work uses the materials of official statistics of the Federal State Institution of Rospotrebnadzor for RS (Y) and information from the register «Chronic viral hepatitis in RS (Y). To assess the burden of disease, the main scenarios were analyzed using the dynamic Excel model.Results and discussion. RS (Y) is a disadvantaged territory of the Russian Federation for parenteral viral hepatitis, including hepatitis C. According to the register «Chronic viral hepatitis in RS (Y)», 14643 people are registered, of which with chronic hepatitis C — 7395, which amounted to 50,5%. The proportion of HCV infection in the group of people with cirrhosis is 44.1%, with hepatocellular carcinoma 59,3%, and 76% in the total structure of the dead. Implementation of the WHO scenario for hepatitis C will reduce mortality by 65%, the number of people with hepatocellular carcinoma by 66%, decompensated cirrhosis by 66% and reduce the overall incidence by 34% by 2030.Conclusion. Achieving the WHO goals by 2030 seems realistic when creating a regional strategy to eliminate HCV in RS (Y), which includes increasing access to therapy with modern drugs with direct antiviral effects, an interdisciplinary approach to the diagnosis and management of patients with chronic hepatitis C, specialties about the problem of chronic hepatitis C and the possibility of curing it.


2021 ◽  
Vol 104 (3) ◽  
pp. 396-401

Background: Chronic viral hepatitis B (CHB) and chronic viral hepatitis C (CHC) are important causes of chronic liver disease and cancer development in patients with progressive fibrosis, which are often associated with hepatic steatosis. Objective: To evaluate the prevalence of hepatic steatosis in Thai CHB and CHC patients and its correlation with fibrosis stage. Materials and Methods: The authors examined the liver biopsy findings of CHB and CHC patients diagnosed at Srinagarind Hospital between 2016 and 2018. Routine Hematoxylin and Eosin staining with PAS, and Masson trichrome staining were used to evaluate fibrosis and steatosis histology according to the METAVIR and SAF scoring systems. The association were evaluated by chi-square, Fisher’s exact, and Spearman’s correlation tests with statistical significance defined as p-value less than 0.05. Results: One hundred thirty-eight cases were examined. The mean age of the patients was 45 years. Chronic hepatitis C was detected in 96 patients (69.6%), and CHB was detected in 42 patients (30.4%). Liver biopsies showed steatosis in 73 patients (52.9%; grade 1: 67.1%, grade 2: 19.2%, and grade 3: 13.7%). Steatosis was associated with viral hepatitis profile (OR 2.534, 95% CI 1.087 to 5.904, p=0.031); however, the METAVIR fibrosis stage associated with the age of the patient (OR 1.059, 95% CI 1.012 to 1.109, p=0.014) and METAVIR activity (OR 4.924, 95% CI 2.443 to 9.967, p<0.0001). Conclusion: Hepatic steatosis is commonly present in Thai CHC and CHB patients, and especially in the former. Steatosis was associated with viral hepatitis profile. Hepatic fibrosis is associated only with the age of the patient and METAVIR activity. Keywords: Chronic hepatitis B, Chronic hepatitis C, Steatosis, Fibrosis, METAVIR, SAF score, Liver biopsy


2004 ◽  
Vol 15 (6) ◽  
pp. 313-326 ◽  
Author(s):  
Morris Sherman ◽  
Vincent Bain ◽  
Jean-Pierre Villeneuve ◽  
Robert P Myers ◽  
Curtis Cooper ◽  
...  

Several government and nongovernment organizations held a consensus conference on the management of acute and chronic viral hepatitis to update previous management recommendations. The conference became necessary because of the introduction of new forms of therapy for both hepatitis B and hepatitis C. The conference issued recommendations on the investigation and management of chronic hepatitis B, including the use of lamivudine, adefovir and interferon. The treatment of hepatitis B in several special situations was also discussed. There were also recommendations on the investigation and treatment of chronic hepatitis C and hepatitis C-HIV coinfection. In addition, the document makes some recommendations about the provision of services by provincial governments to facilitate the delivery of care to patients with hepatitis virus infection. The present document is meant to be used by practitioners and other health care providers, including public health staff and others not directly involved in patient care.


BMC Nursing ◽  
2019 ◽  
Vol 18 (1) ◽  
Author(s):  
Ying’ai Cui ◽  
Michiko Moriyama ◽  
Kazuaki Chayama ◽  
Yanhui Liu ◽  
Chunmei Ya ◽  
...  

Abstract Background Chronic hepatitis, mainly B or C, increases the risk of hepatocellular carcinoma and remains an emerging issue in the globe. China has high rates of liver cancer incidence and mortality in the world. To address such challenges, adequate management of chronic hepatitis is required. Self-management education is one alternative for improving the hepatitis patients’ knowledge of the disease, mental health, and clinical management. This study aimed to examine the quality of life (QOL), psychological effects, and behavioral changes of a self-management program which allows continuity of care for chronic hepatitis B and C patients. Method In a six-month, randomized controlled trial, we invited 73 chronic hepatitis B/C inpatients to receive (i) two face-to-face education sessions provided by a nurse during hospitalization, and monthly telephone counseling at home after discharge; (ii) or usual care treatment (control group). The primary endpoint (patients’ QOL) and secondary outcomes (including self-efficacy, depression symptoms, perceived cognition of illness and behavioral changes) were assessed. In addition, we conducted qualitative data analysis to facilitate the evaluation of the interventions. Results Sixty (82.2%) out of 73 eligible patients with chronic hepatitis B/C (aged 34.9 ± 8.9 years) participated in the study. The intervention group (n = 30) significantly improved on outcomes including QOL, self-efficacy, perceived cognition of illness, and behavioral changes, whereas the control group significantly decreased their healthy behaviors. In terms of behavioral changes, alcohol avoidance, dietary adherence, and stress management also improved in the intervention group. However, there were no significant improvements in symptoms of depression. Most participants (80%) in the intervention group stated that they benefited from the program. Conclusions This program contributed to patients’ acquisition of self-management skills to cope with their illnesses, and significantly improved their QOL. This program serves as a reminder for nurses who care for patients with chronic viral hepatitis to acquire these skills as it would help them address the daily needs of their patients. Trial registration UMIN000025378. Registered December 23, 2016.


Hepatology ◽  
1997 ◽  
Vol 25 (1) ◽  
pp. 229-234 ◽  
Author(s):  
R. Mazzanti ◽  
L. Messerini ◽  
L. Monsacchi ◽  
G. Buzzelli ◽  
A. L. Zignego ◽  
...  

2005 ◽  
Vol 17 (11) ◽  
pp. 1243-1245 ◽  
Author(s):  
Federica Villa ◽  
Maria Grazia Rumi ◽  
Clementina Signorelli ◽  
Simone Saibeni ◽  
Ersilio Del Ninno ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document